Evidence map›Paper›PMID 38072909›Full record

ArticleInsights into imaging2023

Quantification and significance of extraprostatic findings on prostate MRI: a retrospective analysis and three-tier classification.

Monika Wagnerova, Iva Macova, Petr Hanus, Martin Jurka, Otakar Capoun, Lukas Lambert, Andrea Burgetova

Open access · goldAbstract read
In one paragraph

Article in Insights into imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Monika WagnerovaDepartment of Radiology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 2, 128 08, Czech Republic.
Iva MacovaDepartment of Radiology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 2, 128 08, Czech Republic.
Petr HanusDepartment of Radiology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 2, 128 08, Czech Republic.
Martin JurkaDepartment of Radiology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 2, 128 08, Czech Republic.
Otakar CapounDepartment of Urology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 2, 128 08, Czech Republic.
Lukas LambertDepartment of Radiology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 2, 128 08, Czech Republic. lukas.lambert@vfn.cz.ORCID http://orcid.org/0000-0003-2299-4707
Andrea BurgetovaDepartment of Radiology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague 2, 128 08, Czech Republic.
Charles University · CZ

Funding

Charles University in Prague Basic Medical SciencesCharles University in Prague CooperatioCharles University in Prague Medical DiagnosticsMinistry of Health of the Czech Republic 00064165Ministry of Health of the Czech Republic General University Hospital in Prague-VFNMinistry of Health of the Czech Republic MH CZ-DRO
6 · The paper itself

Abstract

objectivesTo quantify extraprostatic findings (EPFs) on prostate MRI, estimate the proportion of reported and unreported EPFs, assess their clinical importance, and propose standardized reporting of EPFs. MATERIALS AND

methodsProstate 3-T MRI studies, reports, and clinical data from 623 patients (age 67.9 ± 8.2 years) were retrospectively analyzed and re-evaluated for the presence of EPFs and their clinical significance: E1-no finding or findings that have no clinical significance; E2-potentially significant findings; and E3-significant findings.

resultsSecondary reading identified 1236 EPFs in 593 patients (1.98 ± 1.13 EPFs per patient, no EPFs in 30 patients), from which 468 (37.8%) were mentioned in the original report. The most common findings included diverticulosis (44% of patients), hydrocele (34%), inguinal fat hernia (16%), and bladder wall trabecular hypertrophy (15%). There were 80 (6.5%) E2 EPFs and 30 (2.4%) E3 EPFs. From E3 EPFs, 10 (33%) were not originally reported. A workup was suggested in 35 (52%) of the 67 originally reported E2 and E3 findings with follow-up and performed in 20 (30%). Fourteen (21%) EPFs in 11 patients influenced their management. Four experienced radiologists originally reported 1.8 to 2.5 findings per patient (p < 0.0001).

conclusionsEPFs on prostate MRI are frequent, but only 2.4% are clinically significant (E3), and 33% of these are not reported. Only 30% of E2 and E3 findings are further explored, and 21% influence patient management. We suggest that an "E" category should be attached to the PI-RADS system to identify the presence of EPFs that require further workup. CRITICAL RELEVANCE STATEMENT: Extraprostatic findings on prostate MRI are frequent, but only 2.4% are clinically significant (E3), and 33% of these are not reported. We advocate standardized reporting of extraprostatic findings indicating their clinical significance. KEY POINTS: • Extraprostatic findings on prostate MRI are frequent with an average of two findings per patient. • 2.4% of extraprostatic findings are significant, and 33% of these are not reported. • There is a significant variability among experienced radiologists in reporting extraprostatic findings.

Indexed as

CancerExtraprostatic findingsMagnetic resonance imagingPI-RADSProstate

Identifiers

PMID38072909
PMCPMC10710974
OpenAlexW4389517376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.